Search
Fluspirilene
go.drugbank.com/drugs/DB04842ApprovedWithdrawnA long-acting injectable antipsychotic agent used for chronic schizophrenia.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesFebuxostat
go.drugbank.com/drugs/DB04854ApprovedInvestigationalFebuxostat is a non-purine xanthine oxidase (XO) inhibitor. In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. In the following year, the FDA for ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesDexloxiglumide
go.drugbank.com/drugs/DB04856InvestigationalDexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesVoacamine
go.drugbank.com/drugs/DB04877ExperimentalVoacamine is an alkaloid isolated from the bark of the Pescheria fuchsiae folia tree. It is an antimalarial drug approved for use in several African countries. Voacamine is also under investigation for use in modulating multidrug-resista...
Categories: P-glycoprotein inhibitorsCalanolide A
go.drugbank.com/drugs/DB04886InvestigationalCalanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity. Both drugs are being developed by Sarawak...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBicifadine
go.drugbank.com/drugs/DB04889InvestigationalBicifadine (DOV-220075) is a nonopioid analgesic. It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile. Bicifadine was shown to have potent analgesic activity in vivo...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesRifalazil
go.drugbank.com/drugs/DB04934InvestigationalRifalazil is a derivative of the antibiotic rifamycin. It is being investigated by ActivBiotics for the treatment of various bacterial infections.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLofexidine
go.drugbank.com/drugs/DB04948ApprovedInvestigationalLofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesTipifarnib
go.drugbank.com/drugs/DB04960InvestigationalTipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. ...
Categories: P-glycoprotein inhibitorsGanaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigationalGanaxolone is the 3β-methylated synthetic analog of allopregnanolone, a metabolite of progesterone. Ganaxolone belongs to a class of compounds referred to as neurosteroids. Endogenous neurosteroids, which comprise certain metabolites of ...
Categories: Cytochrome P-450 Substrates, Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator